A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal paragangliomas
- PMID: 2684087
A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal paragangliomas
Erratum in
- Arch Pathol Lab Med 1990 Mar;114(3):308
Abstract
This review summarizes our understanding of extra-adrenal paragangliomas, a subject that has evolved considerably during the past several years. Our object was to review the anatomical, histologic, and biological features of normal and neoplastic glands, with emphasis on immunohistologic studies, and briefly discuss the potential application of nucleic acid hybridization. Since it is difficult to predict clinical outcome for patients with paragangliomas, we have emphasized the differences between benign and malignant paragangliomas, concentrating on recent results obtained using immunohistologic techniques. These studies have emphasized the critical importance of the identification, by immunohistologic means, of two distinct cell populations, chief cells (type I) and sustentacular cells (type II). The relationship between these two cell populations, stable in normal glands and benign tumors, is progressively lost in tumors of increasing degrees of malignancy, sustentacular cells being absent from the most progressively metastasizing paragangliomas.
Similar articles
-
Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas.Arch Pathol Lab Med. 1993 Nov;117(11):1142-7. Arch Pathol Lab Med. 1993. PMID: 8239937
-
Pathology of pheochromocytoma and extra-adrenal paraganglioma.Ann N Y Acad Sci. 2006 Aug;1073:557-70. doi: 10.1196/annals.1353.059. Ann N Y Acad Sci. 2006. PMID: 17102124
-
Demonstration of S-100 protein in sustentacular cells of phaeochromocytomas and paragangliomas.Histopathology. 1986 Oct;10(10):1023-33. doi: 10.1111/j.1365-2559.1986.tb02539.x. Histopathology. 1986. PMID: 3536711
-
Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.Horm Metab Res. 2009 Sep;41(9):680-6. doi: 10.1055/s-0029-1214381. Epub 2009 Apr 2. Horm Metab Res. 2009. PMID: 19343618 Review.
-
Paragangliomas: etiology, presentation, and management.Cardiol Rev. 2009 Jul-Aug;17(4):159-64. doi: 10.1097/CRD.0b013e3181a6de40. Cardiol Rev. 2009. PMID: 19525677 Review.
Cited by
-
Recurrent paraganglioma of Meckel's cave: Case report and a review of anatomic origin of paragangliomas.Surg Neurol Int. 2011;2:45. doi: 10.4103/2152-7806.79763. Epub 2011 Apr 19. Surg Neurol Int. 2011. PMID: 21660268 Free PMC article.
-
Mediastinal paraganglioma presenting as an intracardiac mass with SVC obstruction.Thorax. 1994 Jun;49(6):625. doi: 10.1136/thx.49.6.625-a. Thorax. 1994. PMID: 8016812 Free PMC article. No abstract available.
-
Immunohistochemical features of paragangliomas.J Cell Mol Med. 2001 Jul-Sep;5(3):311-6. doi: 10.1111/j.1582-4934.2001.tb00165.x. J Cell Mol Med. 2001. PMID: 12067490 Free PMC article.
-
Primary paraganglioma of the spine: A clinicopathological study of eight cases.J Craniovertebr Junction Spine. 2014 Jan;5(1):20-4. doi: 10.4103/0974-8237.135211. J Craniovertebr Junction Spine. 2014. PMID: 25013343 Free PMC article.
-
Imaging findings of lesions in the middle and posterior mediastinum.Jpn J Radiol. 2021 Jan;39(1):15-31. doi: 10.1007/s11604-020-01025-0. Epub 2021 Jan 18. Jpn J Radiol. 2021. PMID: 32740793 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous